VivoSeq
Other

Flushing

16

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Flushing is an emerging landscape with 16 programs across 9 companies. The most active players are Viatris Specialty LLC, Merck & Co., Biogen. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 3Biogen logo

Biogen

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3AbbVie logo

AbbVie

2 programs

Phase 3Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

22 of 23 classified programs — the dominant modality here.

4%ALL OTHERSProtein / enzyme14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

25

clinical trials

Completed17 · 68%
Unknown status4 · 16%
Terminated2 · 8%
Active, not recruiting1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency
Recruiting·NNational University of Malaysia·N/A·NCT06314620·40 enrolled
Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:
Active, not recruiting·—·Phase 4·NCT04379973·736 enrolled
Alternative Options to Minimize Niacin-Induced Flushing
Completed·PPatrick Moriarty, MD, FACP, FACC·N/A·NCT00895193·100 enrolled
Intrauterine Flushing With Follicular Fluid Plus Granulosa Cells
Completed·RRoyan Institute·Phase 3·NCT04077970·140 enrolled
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00533611·330 enrolled
Flushing Reduction Associated With Nitrates
Completed·—·Phase 2·NCT02714205·141 enrolled
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
Completed·Biogen logoBiogen·Phase 3·NCT01568112·173 enrolled
PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine
Completed·DDanish Headache Center·N/A·NCT03881644·37 enrolled
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
Completed·AAbbott·Phase 3·NCT00630877·276 enrolled
Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
Completed·AAbbott·Phase 3·NCT00626392·277 enrolled
A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children
Completed·NNemours Children's Clinic·Phase 4·NCT02435069·5 enrolled
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Completed·RRepublican Scientific and Practical Center for Organ and Tissue Transplantation·N/A·NCT01887171·86 enrolled
Effects of Different Concentrations of Pressurized-heparin Flushing Fluid on Coagulation and Platelet Function Monitored by the Sonoclot Analyzer
Completed·YYangzhou University·N/A·NCT04355273·60 enrolled
Effect of CD07805/47 Gel in Rosacea Flushing
Completed·GGalderma R&D·Phase 2·NCT02300129·34 enrolled
Role of Prostaglandins on Niacin-Induced Flushing
Completed·—·N/A·NCT00930839·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)